Sun Pharma wins Indian approval for a generic semaglutide injection

Sun Pharmaceutical Industries said on January 23, 2026, that India's Drugs Controller General (DCGI) approved its generic semaglutide injection for chronic weight management ^[1]. The company said it would sell the product under the brand name Noveltreat once semaglutide's patent expires in India in March 2026 ^[1]. Sun Pharma also holds a December 2025 DCGI approval for a semaglutide injection for type 2 diabetes, to be sold as Sematrinity ^[1].

Noveltreat comes in five dose strengths — 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg — given once weekly through a prefilled pen, with 2.4 mg as the maintenance dose ^[1]. When Sun Pharma actually launched the two products on March 21, 2026, it said monthly therapy costs would run about ₹900 to ₹2,000 for Noveltreat and ₹750 to ₹1,300 for Sematrinity ^[1]. Separately, CNBC reported that Sun Pharma's generic semaglutide launched at as low as 750 rupees (about $8) per weekly injection, or roughly 3,400 rupees a month — a figure that differs from the therapy-cost range Sun Pharma itself disclosed, and the sources do not reconcile the gap ^[1][2].

Sun Pharma was not alone. Dr. Reddy's Laboratories launched its brand, Obeda, at about ₹4,200 a month (roughly $16 to $17) and said it was the first semaglutide injection approved by India's regulator ^[1][2]. Natco Pharma priced a vial formulation at 1,250 rupees a month, and Alkem Laboratories introduced prefilled injections starting at 1,800 rupees a month — discounts of nearly 80% versus Novo Nordisk's original Indian pricing ^[2]. Novo's own retail price in India ran between 8,800 and 10,000 rupees depending on dosage before the patent lapsed, and the company had already cut Wegovy's price by 37% in India ahead of the expiry ^[2]. More than 50 branded generic versions of semaglutide are expected to launch in India in the coming months ^[2]. India's GLP-1 drug sales have grown quickly, with one industry tracker showing a 178% year-over-year jump in February to 14.46 billion rupees ^[2].

Why it matters for patients

For people in the United States, this development does not change anything about their own access or cost today. Semaglutide remains patent-protected in the U.S., its largest market, until 2032, so no generic version can legally be sold here as a result of India's patent expiry ^[2]. Novo Nordisk has said global sales could fall 5% to 13% in 2026 as patents lapse in India, Canada, Brazil and China, but the company is defending its market position in those countries through price cuts and new co-marketed brands rather than exiting them ^[2]. Analysts quoted by CNBC say Novo could keep much of its Indian market share if it prices only modestly above generics, while others note that generic manufacturers have historically struggled to match Novo's scale ^[2]. One industry expert also raised a concern relevant to drug safety broadly: peptide-based medicines like semaglutide require more complex quality control than typical generic pills, and quality control in India is still described as catching up to European or U.S. standards ^[2]. There is no indication in the sources that generic semaglutide made for India is legally available to U.S. patients, and buying imported or unapproved versions carries risks that are not addressed here.

What happens next

Semaglutide's patent in India expired on Friday, March 20, 2026, clearing the way for the wave of launches reported over that weekend ^[2]. Dr. Reddy's has said it plans to expand its semaglutide sales to Canada, Turkey and Brazil later in 2026, part of a broader pattern of patent expirations in multiple countries outside the U.S. this year ^[2]. No date for a U.S. generic entry is mentioned in the available sources, consistent with the 2032 patent protection cited by CNBC ^[2].